Every Form 4 that Staar Surgical Co (STAA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow STAA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STAA filings page.
STAAR SURGICAL CO (STAA) reported multiple equity awards to President and CEO Warren Foust on August 14, 2026. He received 22,493 restricted stock units, each RSU convertible into one share of common stock, vesting over three years. He was granted stock options for 40,471 and 37,962 shares at an exercise price of $26.18 per share, plus performance stock options for 131,830 and 123,659 shares, also at $26.18, which vest based on both time and stock-price hurdles of $50.00, $75.00 and $100.00 per share. In addition, third tranches of performance stock units of 7,331 and 3,666 units vested, settling into common stock, with 3,730 and 1,865 shares, respectively, withheld to satisfy taxes.
STAAR Surgical Co (STAA) reported equity compensation and vesting events for its Chief Financial Officer & EVP, Deborah J. Andrews. On August 14, 2026, she received 4,975 Restricted Stock Units, plus a stock option for 8,952 shares at an exercise price of $26.18 per share expiring on August 13, 2036. She also received a performance stock option for 29,159 shares at $26.18 per share, vesting over a performance period with stock-price hurdles of $50.00, $75.00 and $100.00 per share and additional time-vesting conditions. Separately, the third tranche of 5,233 performance stock units under the 2025 PSU Program vested, converting into common shares, of which 2,662 shares were withheld to satisfy taxes.
STAAR SURGICAL CO (STAA) reported that Chief Development Officer Magda Michna settled and exercised performance-based equity awards on August 14, 2026. A third tranche of 5,499 performance stock units from her 2025 annual equity grant and 1,100 units from a promotion-related grant were settled into common stock, totaling 6,599 shares acquired. Of these, 2,797 shares were withheld to satisfy taxes and an additional 559 shares were delivered or withheld for payment of exercise price or tax liability. The company also corrected prior Form 4 filings to reflect lower historical beneficial ownership values.
STAAR Surgical President and CEO Warren Foust reported the vesting and conversion of 20,787 Restricted Stock Units granted on February 2, 2026 in connection with his appointment as Interim Co-Chief Executive Officer. These RSUs vested on July 31, 2026 and converted into common stock on a one-for-one basis. To satisfy obligations associated with this vesting, 10,576 common shares were withheld at $24.36 per share. A footnote also corrects an earlier Form 4, stating his beneficial ownership was 76,345 shares rather than 83,112 in that prior report.
STAAR Surgical reports equity award activity for Chief Financial Officer & EVP Deborah J. Andrews. On June 25 and July 31, 2026, previously granted RSUs vested, converting into a total of 34742 shares of common stock. In related code F transactions, 6480 shares at $31.2100 and 10576 shares at $24.3600 per share were disposed of to pay exercise price or tax liability, with no open-market purchases or sales reported.
STAAR Surgical director Christopher Min Fang Wang received a grant of stock options, acquiring rights to 11,145 shares of common stock. The options have an exercise price of $29.12 per share and were granted as compensation, not through open-market buying or selling.
These options vest in full on the earlier of June 18, 2027 or the company’s 2026 annual meeting of shareholders, and expire on June 18, 2036. After this grant, Wang holds 11,145 options directly under this award.
STAAR Surgical director Richard T. LeBuhn received a new stock option grant as part of his director compensation. He was granted options covering 11,145 shares of common stock at an exercise price of $29.12 per share, with no cash paid for the grant.
These options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. LeBuhn also holds previously granted options covering 7,524 shares at an exercise price of $18.46 per share that are currently exercisable and expire in 2036.
STAAR Surgical director Neal C. Bradsher reported a new stock option grant as director compensation. He received options for 11,145 shares of common stock at an exercise price of $29.12 per share, expiring on June 18, 2036.
The new options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, contingent on his continued service. Bradsher also holds previously granted options covering 7,524 underlying shares at an exercise price of $18.46 per share, which are currently exercisable.
STAAR Surgical director Arthur C. Butcher exercised 5,341 restricted stock units into Common Stock on June 18, 2026, bringing his direct Common Stock holdings to 9,549 shares.
He also received 3,709 new restricted stock units and 4,458 stock options at a $29.12 exercise price, which vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.
Zhou Lilian Yansheng reported acquisition or exercise transactions in this Form 4 filing.
STAAR Surgical director Lilian Yansheng Zhou received new equity awards as part of the company’s annual non-employee director compensation for the 2026-2027 term. On June 18, 2026, Zhou was granted options to purchase 5,572 shares of common stock at $29.12 per share, expiring June 17, 2036.
Zhou also received 3,091 restricted stock units tied to common stock. According to the grant terms, both the options and the restricted stock units vest in full on the earlier of June 18, 2027 or STAAR Surgical’s 2027 Annual Meeting of Shareholders.
STAAR Surgical director Lou Silverman reported compensation-related equity activity. He exercised 10,683 previously granted restricted stock units into an equal number of common shares and now directly holds 11,158 shares. On the same date, he received a new grant of 6,182 restricted stock units for the 2026–2027 non‑employee director term, which will vest in full on the earlier of June 18, 2027 or the company’s 2027 annual shareholder meeting. All transactions reflect equity awards and exercises rather than open‑market buying or selling.
STAAR Surgical director Jiang Wei reported equity compensation transactions involving company stock. On June 18, 2026, Jiang Wei exercised 10,683 previously granted restricted stock units into 10,683 shares of common stock, increasing direct common share holdings to 77,127 shares after the transactions.
On the same date, Jiang Wei received a new grant of 6,182 restricted stock units under the annual non-employee director equity compensation program for the 2026-2027 term. These new units are scheduled to vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.
STAAR Surgical director Lilian Yansheng Zhou acquired 3,530 shares of common stock on June 12, 2026 as a grant or award-type transaction. The weighted average price reported was $28.2904 per share, based on multiple trades between $28.215 and $28.35. Following this acquisition, Zhou directly holds 8,101 shares of STAAR Surgical common stock.
STAAR Surgical interim Co-CEO and CFO Deborah J. Andrews reported equity compensation activity tied to performance stock units that vested on May 15, 2026. Two tranches of performance stock units under the 2025 PSU Program settled into 10,466 and 5,233 shares of common stock after the Compensation Committee certified performance results.
To cover tax obligations on these vestings, the company withheld 3,755 and 1,877 shares, reported as tax-withholding dispositions at about $32.07 per share. After these non‑market transactions, Andrews directly held 15,297 shares of STAAR Surgical common stock. The filing reflects routine compensation and tax withholding, not open‑market buying or selling.
STAAR Surgical’s interim co-CEO and President & COO Warren Foust reported routine equity compensation activity tied to performance stock units on May 15, 2026. Several tranches of 2025 performance stock units vested and were settled into common shares, with a portion of the shares withheld to cover tax obligations at $32.07 per share. Following these transactions, Foust directly held 83,112 shares of common stock.
STAAR Surgical Chief Development Officer Magda Michna reported compensation-related share activity tied to performance stock units. On May 15, 2026, multiple tranches of 2025 Performance Stock Units vested and were settled into a total of 19,795 shares of common stock. To cover tax obligations, 9,703 shares were withheld at a price of $32.07 per share. After these settlements and withholdings, Michna directly holds 38,093 shares of common stock and 10,997 remaining performance stock units.
STAAR Surgical's Interim Co-CEO and President & COO Warren Foust reported a tax-related share disposition linked to previously granted restricted stock units. On May 8, 2026, 3,448 shares of common stock were withheld at $26.69 per share to satisfy tax obligations when RSUs vested. These RSUs were part of a grant made on May 8, 2023, vesting in three equal installments of 6,777 shares on May 8 of 2024, 2025, and 2026. After this tax-withholding event, Foust directly held 66,917 shares of STAAR Surgical common stock.
STAAR Surgical’s Chief Development Officer Magda Michna reported a routine tax-related share disposition. On May 8, 2026, 1,680 shares of common stock were withheld at $26.69 per share to cover taxes on previously granted restricted stock units that vested on that date.
The RSUs were granted on May 8, 2023 and vested in three roughly equal annual installments through May 8, 2026. After the tax withholding, Michna directly owns 32,691 shares of STAAR Surgical common stock. The filing also corrects a prior typo in reported holdings, confirming the correct earlier total was 29,688 shares.
ANDREWS DEBORAH J reported acquisition or exercise transactions in this Form 4 filing.
STAAR Surgical granted Interim Co-CEO and CFO Deborah J. Andrews 39,809 restricted stock units (RSUs) on March 13, 2026 as an annual equity award. Each RSU represents one share of common stock and vests in three equal installments through March 13, 2029.
STAAR Surgical’s interim co-CEO and president & COO Warren Foust reported equity compensation activity, mainly from restricted stock units (RSUs). On March 13, 2026, he received a grant of 45,117 RSUs, which will vest in three equal annual installments starting in 2027.
On March 12 and 14, 2026, previously granted RSUs vested and were converted into common stock through option code M transactions, totaling 37,500 shares acquired. Following these events, he directly held 63,588 shares of common stock and 45,117 RSUs subject to future vesting.
STAAR Surgical’s Chief Development Officer Magda Michna reported several equity compensation events. On March 13, 2026, she received a grant of 33,838 restricted stock units (RSUs), which are scheduled to vest in three equal tranches in 2027, 2028, and 2029.
On March 12 and 14, 2026, previously granted RSUs vested and were converted into a total of 23,773 shares of common stock. In connection with these vestings, the company withheld 2,216 shares at $18.39 and 6,313 shares at $18.84 to cover tax obligations, which is recorded as a disposition but not an open‑market sale. Following these transactions, Michna directly holds 29,668 shares of common stock, along with RSUs that remain subject to future vesting.
Broadwood Partners, L.P., a more-than-10% owner and director affiliate of STAAR Surgical, reported a series of open-market purchases of Common Stock. Between March 11 and March 13, Broadwood Partners bought a total of 670,213 shares at weighted average prices ranging from about $17.18 to $18.84 per share, with specific daily averages of $17.5217, $18.1154, and $18.6150.
After these transactions, Broadwood Partners directly owned 16,123,842 shares of STAAR Surgical Common Stock. The filing notes that these securities are directly owned by Broadwood Partners and may be deemed indirectly beneficially owned by Broadwood Capital, Inc., as its general partner, and by Neal C. Bradsher, as President of Broadwood Capital. Each reporting person disclaims beneficial ownership beyond their economic interest. A separate holding entry shows 25,900 shares directly owned by Neal C. Bradsher.
STAAR Surgical director and 10% owner Neal C. Bradsher received an option grant to purchase 7,524 shares of common stock at an exercise price of $18.46 per share. The options expire on March 5, 2036 and are held directly.
The options will vest and become exercisable on the earlier of June 18, 2026 or the date of the company’s 2026 annual shareholder meeting, subject to his continuous service as a director. The grant was made on March 6, 2026 as director compensation under STAAR Surgical’s Amended and Restated Omnibus Equity Incentive Plan. Following this grant, Bradsher holds 7,524 options to purchase common stock.
STAAR Surgical director Richard T. LeBuhn received a grant of stock options as compensation. On March 6, 2026, he was awarded options to purchase 7,524 shares of common stock at an exercise price of $18.46 per share under the company’s Amended and Restated Omnibus Equity Incentive Plan.
The options vest and become exercisable on the earlier of June 18, 2026 or the company’s 2026 annual meeting of shareholders, as long as he continues serving the company. The options expire on March 5, 2036, and following this grant he holds 7,524 options directly.
STAAR Surgical director Christopher Min Fang Wang received a grant of stock options covering 7,524 shares of common stock. The options have an exercise price of $18.46 per share and expire on March 5, 2036. They vest in full on the earlier of June 18, 2026 or the company’s 2026 annual shareholder meeting.
STAAR Surgical granted restricted stock units to Interim Co-CEO and President & COO Warren Foust. On February 2, 2026, he received 20,787 RSUs, each representing one share of common stock upon vesting at a price of $0 per unit.
The RSUs will vest as to 100% of the shares on August 1, 2026, assuming the vesting conditions are met. Following this grant, Foust beneficially owns 20,787 derivative securities directly in the form of these RSUs.
STAAR Surgical reported an equity award to interim executive Deborah J. Andrews, who serves as Interim Co-CEO and CFO. On February 2, 2026, she received 20,787 restricted stock units (RSUs) at a price of $0. Each RSU represents the right to receive one share of common stock upon vesting.
The RSU grant was made in connection with her appointment as Interim Co-Chief Executive Officer. All 20,787 RSUs will vest 100% on August 1, 2026, if the vesting conditions are met, giving her direct beneficial ownership of the underlying shares upon settlement.
STAAR Surgical director Wei Jiang reported the vesting and conversion of restricted stock units into common shares. On January 12, 2026, 20,967 restricted stock units granted on May 12, 2025 vested and were converted into 20,967 shares of STAAR Surgical common stock at an exercise price of $0 per share. These units were the final third of an award that vested in three equal installments on August 12, 2025, November 12, 2025, and January 12, 2026. Following this transaction, Jiang directly beneficially owned 66,444 shares of STAAR Surgical common stock.
Broadwood Partners, L.P., a 10% owner of STAAR Surgical, reported buying 27,485 shares of common stock on January 9, 2026 at a weighted average price of $22.0534 per share, bringing its directly owned stake to 15,453,629 shares.
These shares are held by Broadwood Partners and may be deemed indirectly beneficially owned by Broadwood Capital, Inc. and its president, Neal C. Bradsher, who also directly owns 25,900 shares of STAAR Surgical common stock.
Broadwood Partners, L.P., a 10% owner of STAAR Surgical Co. (STAA), reported open‑market purchases of the company’s common stock in early January 2026. Broadwood Partners bought 186,946 shares at a weighted average price of $21.0111 and 150,000 shares at $22.3756 on January 6, followed by 66,467 shares at $22.0004 on January 7 and 3,240 shares at $21.9389 on January 8. After these transactions, Broadwood Partners reported holding 15,426,144 shares of STAAR Surgical common stock. A separate holding of 25,900 STAAR Surgical shares is reported as being directly owned by Neal C. Bradsher. The filing notes that Broadwood Capital, Inc. and Neal C. Bradsher may be deemed indirect beneficial owners through their roles with Broadwood Partners, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
STAAR Surgical's Chief Legal Officer, Nathnaniel B. Sisitsky, reported an equity transaction involving company common stock. On December 11, 2025, restricted stock units granted on December 11, 2023 vested as to 7,312 shares.
Upon vesting, 2,616 shares of common stock were withheld to satisfy taxes at a reported price of $24.68 per share. After this tax withholding, Sisitsky beneficially owned 22,812 shares of STAAR Surgical common stock, which includes previously granted RSUs that are still subject to future vesting.
Broadwood Partners, L.P. and related parties reported open-market purchases of STAAR Surgical (STAA) common stock. On 11/19/2025, they purchased 309,132 shares at a weighted average price of $26.4164. On 11/20/2025, they purchased 393,382 shares at a weighted average price of $27.1373, and on 11/21/2025 they purchased 797,486 shares at a weighted average price of $27.8611.
Following these transactions, Broadwood Partners directly beneficially owned 15,019,491 shares of common stock, and 25,900 shares were directly owned by Neal C. Bradsher. The reporting persons include Broadwood Partners, L.P., Broadwood Capital, Inc. and Neal C. Bradsher, who is identified as a director and 10% owner. The parties state that each disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest.
STAAR Surgical (STAA) reported an insider equity change on Form 4. On 11/12/2025, Director Wei Jiang acquired 20,967 shares of common stock at $0 per share, following the vesting and settlement of restricted stock units (Transaction Code: M).
After this transaction, Jiang beneficially owns 45,477 shares, held directly. The RSUs were granted on May 12, 2025 and vest in three equal tranches of 20,967 shares each: on August 12, 2025, November 12, 2025, and January 12, 2026.
According to prior disclosures, Jiang is serving through fiscal 2025 as a special strategic advisor to the company’s Asia Pacific business in the temporary role of Chief of APAC Strategy; this transaction reflects vesting tied to that service.